Aronson R, et al. - The efficacy and safety of ertugliflozin monotherapy were evaluated in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c] 7.0% to 10.5% [53-91 mmol/mol]) despite diet and exercise. Improved glycaemic control and reduced body weight and systolic blood pressure (SBP) were noted with ertugliflozin treatment over 52 weeks. However, it increased genital mycotic infections (GMIs).